Oculis is a biopharmaceutical company purposefully driven to save sight & improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. Headquartered in Switzerland, Oculis’ goal is to deliver life-changing treatments to patients worldwide.
Products, services, technology
OCS-01 being developed in DME and Inflammation and Pain following ocular surgery
OCS-02 being developed for Dry Eye Disease and Uveitis
OCS-05 being developed for neuro-ophthalmic diseases
Pre-clinical candidates for retinal disorders and for ocular inflammation
- http://www.oculis.com
- +41 21 711 39 70
- louie-anne.gauthier@oculis.com
- Louie-Anne Gauthier
